Cargando…

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study

Patients with peripheral arterial disease (PAD) benefit from combination therapy with acetylsalicylic acid (ASA, 100 mg, one time per day) plus low-dose rivaroxaban (2.5 mg, two times per day) compared to ASA monotherapy. In particular, major adverse cardiac and limb events were significantly reduce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurk, Kerstin, Rothenaicher, Korbinian F., Groß, Kathrin, Rossmann, Heidi, Weißer, Gerhard, Schmidtmann, Irene, Münzel, Thomas, Espinola-Klein, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120432/ https://www.ncbi.nlm.nih.gov/pubmed/35600474 http://dx.doi.org/10.3389/fcvm.2022.865166

Ejemplares similares

Antithrombotic therapy in peripheral arterial disease
por: Espinola-Klein, Christine, et al.
Publicado: (2022)

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial
por: Schnorbus, Boris, et al.
Publicado: (2021)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study
por: Schnorbus, Boris, et al.
Publicado: (2014)

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease
por: Baidildinova, Gaukhar, et al.
Publicado: (2021)

Use of oral rivaroxaban in cerebral venous thrombosis
por: Maqsood, Muhammad, et al.
Publicado: (2020)

Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project
por: Frank, Bernd, et al.
Publicado: (2015)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Influence of Sex on Platelet Reactivity in Response to Aspirin
por: Friede, Kevin A., et al.
Publicado: (2020)

Novel GATA1 Variant Causing a Bleeding Phenotype Associated with Combined Platelet α-/δ-Storage Pool Deficiency and Mild Dyserythropoiesis Modified by a SLC4A1 Variant
por: Jurk, Kerstin, et al.
Publicado: (2022)

Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders
por: Kuliczkowski, Wiktor, et al.
Publicado: (2021)

Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Puccini, Marianna, et al.
Publicado: (2022)

Platelet Aggregation Before Aspirin Initiation in Pediatric Patients With Congenital Heart Disease at High Risk of Thrombosis
por: Lu, Zhong-Yuan, et al.
Publicado: (2022)

Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay
por: Schenk, B., et al.
Publicado: (2016)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Platelet Endothelial Aggregation Receptor 1 Polymorphism Is Associated With Functional Outcome in Small-Artery Occlusion Stroke Patients Treated With Aspirin
por: Li, Zhizhang, et al.
Publicado: (2021)

Platelet Phenotyping and Function Testing in Thrombocytopenia
por: Jurk, Kerstin, et al.
Publicado: (2021)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
por: Würtz, Morten, et al.
Publicado: (2014)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban—A Case Report
por: Sharma, Harish, et al.
Publicado: (2020)

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study
por: Lee, Meng, et al.
Publicado: (2014)

Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample
por: Hobohm, Lukas, et al.
Publicado: (2022)

Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease
por: Zhang, JW, et al.
Publicado: (2017)

Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor
por: Costa, Thiago Guarato Rodrigues, et al.
Publicado: (2022)

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
por: Cirillo, Plinio, et al.
Publicado: (2020)

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
por: Granero Xiberta, Xavier, et al.
Publicado: (2016)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery
por: Mastenbroek, T. G., et al.
Publicado: (2020)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
por: Mayer, Katharina, et al.
Publicado: (2023)

Platelets, Aspirin and Cardiovascular Disease
por: Elwood, P. C.
Publicado: (1976)

Fifty years with aspirin and platelets
por: Patrono, Carlo
Publicado: (2022)

Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats
por: Soni, Hitesh M., et al.
Publicado: (2014)

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
por: Peacock, W. Frank, et al.
Publicado: (2019)

Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR)
por: Di Santo, Pietro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6u1ddd2al3ivmb79mhikcrhl85